Physician profile
Brooke Drew
NPI 1477830669
$3,655.28
in general payments reported to CMS, 2019-2025
22 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.92 · 2022: $216 · 2023: $760 · 2024: $1,251 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.84 |
| Education | $370.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $626.30 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $430.46 | 2023-2025 | |
| Pfizer INC. | $305.64 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $303.66 | 2022-2025 | Ilumya, Blu-U |
| Genzyme Corporation | $294.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $256.33 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $219.04 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $182.02 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $175.90 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $171.40 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $154.35 | 2023-2025 | Zoryve |
| Ucb, INC. | $105.77 | 2024-2025 | Bimzelx |
| Amgen INC. | $96.88 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $54.10 | 2023-2024 | Vtama |
| Leo Pharma INC. | $53.04 | 2021-2025 | Anzupgo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $50.90 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $50.36 | 2025 | Xtrac |
| Galderma Laboratories, L.P. | $38.97 | 2023-2025 | Nemluvio |
| Allergan, INC. | $29.11 | 2022 | |
| Biofrontera INC. | $21.63 | 2022 | |
| Almirall LLC | $19.22 | 2023 | Seysara |
| Verrica Pharmaceuticals INC. | $16.11 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.